Revimmune cyclophosphamide regulatory update

ABPI received an SPA from FDA for a 1-year Phase III trial of Revimmune cyclophosphamide in 200-300 patients with refractory, relapsing-remitting multiple sclerosis (MS) expected to begin in 1H08 (see...